Olympus Launches THUNDERBEAT Energy Device for Open Surgery
Olympus Launches THUNDERBEAT Energy Device for Open Surgery

TOKYO and CENTER VALLEY, PA., Sep 28, 2022 – (JCN Newswire via SEAPRWire.com) – Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT(TM) Open Fine Jaw Type X surgical energy devices for open surgery. With a new thermal shield, the... » read more

SAMEZIP Launches the Latest Features – Postal Code Area Surcharge Inquiry
SAMEZIP Launches the Latest Features – Postal Code Area Surcharge Inquiry

San Jose, CA, July 23, 2022 – (SEAPRWire) – SAMEZIP launches the latest features – zip code area surcharge inquiry. By entering a five-digit zip code, SAMEZIP.COM can determine whether a zip code belongs to UPS or FedEx system: Regular Area Surcharge; Extended Area Surcharge; Remote Area Surcharge Undeliverable For these five types of zip codes, UPS and FedEx have... » read more

Honda Holds World Premiere of the All-new Civic Type R
Honda Holds World Premiere of the All-new Civic Type R

TOKYO, Jul 21, 2022 – (JCN Newswire via SEAPRWire.com) – Honda Motor Co., Ltd. today held the world premiere of the all-new Civic Type R, which is scheduled to go on sale in Japan in September 2022. At the world premiere, which was held online, Honda unveiled the exterior and interior designs of the all-new... » read more

Toyota’s World Premiere of the All-New Crown Series
Toyota’s World Premiere of the All-New Crown Series

Toyota City, Japan, Jul 15, 2022 – (JCN Newswire via SEAPRWire.com) – TOYOTA has unveiled the all new Crown for the first time in the world, and will release the Crown (Crossover type) as the first model around the fall of this year(1). The Crown made its initial debut in 1955 as Toyota’s first mass... » read more

Honda Launches All-New Civic Type R Teaser Page on its Company Website
Honda Launches All-New Civic Type R Teaser Page on its Company Website

TOKYO, Jul 12, 2022 – (JCN Newswire via SEAPRWire.com) – Honda Motor Co., Ltd. today launched a teaser page on its company website to release initial information on the all-new Civic Type R, which is scheduled to go on sale this fall. Honda will hold the world premiere of the all-new model on Thursday, July... » read more

All-new Civic Type R Sets New Lap Record at Suzuka Circuit
All-new Civic Type R Sets New Lap Record at Suzuka Circuit

TOKYO, Apr 7, 2022 – (JCN Newswire via SEAPRWire.com) – Honda Motor Co., Ltd. today announced that the all-new Honda Civic Type R has set a new lap time record for a front-wheel drive car(1) at the Suzuka Circuit (Suzuka International Racing Course) during testing conducted for the model’s final performance evaluation. The final development... » read more

Hua Medicine Announces 2021 Annual Results

SHANGHAI, CHINA, Mar 17, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the “Reporting Period”). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. The New Drug... » read more

How SEAPRWire team Divide the Types of News releases
How SEAPRWire team Divide the Types of News releases

Hong Kong – Editors at SEAPRWire team deal with different types of press releases on a daily basis. SEAPRWire team are used to classifying it into different types. Each type serves a different purpose and marketing strategy. The type of news release users want to use depends on what users’ company wishes to communicate within the press statement.... » read more

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

SHANGHAI, Sep 26, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (“Hua Medicine”; SEHK: 2552) today announced that at the 6th China BioMed Innovation and Investment Conference held September 25-27 in Suzhou, China (the “CBIIC”), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society,... » read more

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial
Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial

SHANGHAI, CHINA, Dec 18, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: – Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of the COVID-19 global... » read more

AbbVie and Eisai Announce an approval for additional indication of HUMIRA
AbbVie and Eisai Announce an approval for additional indication of HUMIRA

TOKYO, Nov 27, 2020 – (JCN Newswire) – AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”). HUMIRA was granted orphan drug designation for the treatment of PG in... » read more